rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PTGX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Protagonist Therapeutics at Jefferies Global Healthcare Conference: partner-led growth
      Nov 17Investing.comPTGX
      Protagonist Therapeutics at Wolfe Research conference: pipeline gains momentum
      Nov 10Investing.comPTGX
      Wedbush reiterates Protagonist Therapeutics stock rating on oral focus
      Nov 9Investing.comPTGX
      Protagonist Therapeutics (PTGX) Stock Looks Priced At A Premium As Its 7x Three Year Run Continues
      Nov 6Yahoo FinancePTGX
      Protagonist Therapeutics (PTGX) Swung To Profit, Is It A Bargain Or Fully Priced?
      Nov 6Yahoo FinancePTGX
      Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass Estimates
      Nov 5Yahoo FinancePTGX
      Protagonist Therapeutics: Q3 Earnings Snapshot
      Nov 5Yahoo FinancePTGX
      Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update
      Nov 5Yahoo FinancePTGX
      Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
      Oct 29Yahoo FinancePTGX
      Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?

      The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

      Oct 28Yahoo FinancePTGX
      Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026
      Oct 27Yahoo FinancePTGX
      Protagonist Therapeutics Stock: Opt-Out Turned A Biotech Royalty Compounder (NASDAQ:PTGX)
      Oct 25Seeking AlphaPTGX
      Germany's Merck buys Silence Therapeutics in $1.3 billion RNA drug deal
      Oct 19ReutersPTGXSLNMRK
      Protagonist CFO Ali Asif sells $8.3 million in company stock
      Oct 18Investing.comPTGX
      Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know
      Oct 15Yahoo FinancePTGX
      Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today
      Oct 15BenzingaPTGX
      Johnson & Johnson and Protagonist Therapeutics Icotyde: The Best Inventions of 2026

      Find out why Johnson & Johnson and Protagonist Therapeutics Icotyde is on TIME's list of 2026's best inventions.

      Oct 15TimePTGXJNJ
      Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology
      Oct 12Seeking AlphaNKTRPTGXSTTK
      UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target

      Protagonist Therapeutics (PTGX) has an average rating of buy and mean price target of $159.36, accor

      Oct 12Yahoo FinancePTGX
      UBS initiates Protagonist Therapeutics stock with buy rating on drug potential
      Oct 12Investing.comPTGX
      Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today - Protagonist

      Protagonist Therapeutics (NASDAQ:PTGX) has outperformed the market over the past 10 years by 6.99% on an annualized basis producing an average annual return of 20.58%. Currently, Protagonist Therapeutics has a market

      Sep 28BenzingaPTGX
      The Peptide Boom That Isn’t About Your Muscles
      Sep 25WSJPTGX
      Polycythemia Vera Market Size, Emerging Therapies, and Forecast Insights Through 2036 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma
      Sep 25BarchartPTGXSLN
      Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing

      Dinesh V Patel, Director, President and Chief Executive Officer, on September 08, 2026, sold 125,000

      Sep 11Yahoo FinancePTGX
      Protagonist Therapeutics at Cantor conference: cash, launches and pipeline
      Sep 10Investing.comPTGX
      Protagonist Therapeutics CEO sells $18.2m in shares
      Sep 10Investing.comPTGX
      Protagonist Therapeutics authorizes $300 million buyback plan
      Sep 8Investing.comPTGX
      Protagonist Therapeutics Announces $300 Million Share Repurchase Program

      NEWARK, CA / ACCESS Newswire / September 8, 2026 / , Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common stock.

      Sep 8Yahoo FinancePTGX
      Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status

      On August 5, Protagonist Therapeutics (NASDAQ:PTGX) reported second-quarter 2026 results that flipped the company from red ink to a $162.8 million profit, or $2.29 per diluted share, compared with a $34.8 million loss a year earlier. The swing came as the company banked payments tied to two drugs moving from the lab bench to the […]

      Sep 6Yahoo FinancePTGX
      MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?

      U.S. Food and Drug Administration approval of MIMRYLO, or rusfertide, for erythrocytosis in adults with polycythemia vera triggered $275 million in payments to Protagonist Therapeutics, Inc. (NASDAQ:PTGX). The amount consists of an additional $200 million opt-out fee and a separate $75 million approval milestone. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) chose royalties over the original 50:50 U.S. […]

      Sep 4Yahoo FinancePTGX
      Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026

      NEWARK, CA / ACCESS Newswire / September 2, 2026 / (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V., President and Chief Executive Officer, will participate in two investment bank conferences taking place in September 2026.

      Sep 2Yahoo FinancePTGX
      Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)

      Detailed price information for Protagonist Therapeutics Inc (PTGX-Q) from The Globe and Mail including charting and trades.

      Sep 2The Globe and MailPTGXPVLA
      Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News

      Protagonist Therapeutics stock has delivered very strong returns over the past few years, yet the broader valuation checks currently lean toward the shares looking expensive rather than like an obvious bargain. After such a strong move, investors are weighing how much of the good news is already reflected in the price. Over the past 3 years, Protagonist Therapeutics has gained roughly 6.5 times its earlier level. This puts extra focus on whether recent enthusiasm has pushed the valuation...

      Sep 1Yahoo FinancePTGX
      BMO raises Protagonist Therapeutics price target on Mimrylo approval
      Sep 1Investing.comPTGX
      The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones

      Protagonist Therapeutics recently reported that the U.S. FDA approved MIMRYLO (rusfertide), the first hepcidin mimetic peptide therapy for adults with polycythemia vera, a rare blood cancer. This regulatory milestone also activates milestone payments from partner Takeda, underlining how MIMRYLO’s unique mechanism could reshape treatment options in this indication. We’ll now examine how FDA approval of MIMRYLO and the associated Takeda milestone payments influence Protagonist Therapeutics’...

      Sep 1Yahoo FinancePTGXTAK
      Protagonist Therapeutics (PTGX) Could Be 63% Below Fair Value After Investor Update Call

      Why Protagonist Therapeutics Is Back In Focus After Investor Update Call Protagonist Therapeutics (PTGX) has drawn fresh attention after hosting a special call on 29 August 2026 to discuss its latest investor update, prompting many shareholders to reassess the stock. The special call comes after a strong run in Protagonist Therapeutics, with the latest share price at $147.75 and a 90 day share price return of 58.48%, along with a very large 3 year total shareholder return. However, the 7 day...

      Sep 1Yahoo FinancePTGX
      Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)

      Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

      Sep 1The Globe and MailPTGXPVLA
      Why Is Protagonist Therapeutics (PTGX) In Focus After MIMRYLO FDA Approval?

      Protagonist Therapeutics (NasdaqGM: PTGX) reported U.S. FDA approval of MIMRYLO (rusfertide) as a first in class hepcidin mimetic peptide for adults with polycythemia vera. The approval makes MIMRYLO the only FDA approved hepcidin mimetic therapy available for this rare blood cancer. The decision triggers milestone payments from partner Takeda to Protagonist Therapeutics, linked to clinical and commercial progress for MIMRYLO. This approval highlights how drug developers using advanced...

      Sep 1Yahoo FinancePTGX
      Protagonist Therapeutics stock rating maintained at Buy by Clear Street
      Aug 31Investing.comPTGX
      Jefferies reiterates Protagonist Therapeutics stock rating on Mimrylo label strength
      Aug 31Investing.comPTGX
      Wolfe Research reiterates Protagonist Therapeutics stock rating at outperform
      Aug 31Investing.comPTGX
      Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera - Slideshow (NASDAQ:PTGX) 2026-08-31
      Aug 31Seeking AlphaPTGX
      Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. | The Motley Fool

      One of J&J's investments stands head-and-shoulders above the rest.

      Aug 31The Motley FoolFATEPTGXJNJ
      Citigroup Raises Protagonist Therapeutics Price Target to $182 From $175, Buy Rating Kept

      Protagonist Therapeutics (PTGX) has an average rating of buy and mean price target of $159.36, accor

      Aug 31Yahoo FinancePTGX
      Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says

      Protagonist Therapeutics (PTGX) could have attractive commercial potential for Mimrylo following the

      Aug 31Yahoo FinancePTGX
      Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says

      Protagonist Therapeutics' (PTGX) future growth will hinge more on its wholly owned programs than on

      Aug 31Yahoo FinancePTGX
      Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment

      Protagonist Therapeutics (NASDAQ:PTGX) said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia vera, or PV. The approval marks the company’s second FDA-approved medicine this year, following the M

      Aug 31Yahoo FinancePTGX
      Protagonist Therapeutics receives FDA approval for polycythemia vera drug
      Aug 29Investing.comPTGX
      Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

      MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera, Offering a Novel Mechanism to Maintain Hematocrit Control, Meaningfully Reduce Phlebotomy Burden, and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Response During Weeks 20-32FDA Approval Triggers $275M in Milestones, 14%-29% Royalties, with Up to an Additional $875M in Potential Future MilestonesInvestor c

      Aug 29Yahoo FinancePTGX
      US FDA approves Takeda, Protagonist's drug for rare blood cancer
      Aug 28ReutersPTGXTAK

      This is the newest page. Registered accounts read further back.